Tanios Bekaii-Saab, MD

@mayoclinic AZ #Pancreaticcancer #Colorectalcancer #cholangiocarcinoma #Livercancer #Lebanon #Freedom Retweets/Follows not endorsements. Views my own.

[Tanios Bekaii-Saab, MD @GIcancerDoc]

Tanios Bekaii-Saab @MayoCancerCare: Not Just Seeing the Light, But Getting Out of the Tunnel https://t.co/KduB2VnZ5s

[Tanios Bekaii-Saab, MD @GIcancerDoc]

@skopetz @MDAndersonnews @adasarimd Congrats to the 2 of you! and congrats to @MDAndersonnews to have such amazing leaders in the field take on the respective chair roles

[Texas GI Conference @TXGIconference]

Don’t miss the Texas GI Tank at #TexasGI26. 🦈 @KlempnerSam and @rutikamehtaMD go head-to-head on one of the biggest questions in GI oncology: 1L HER2+ Gastric/GEJ – The Role of Immunotherapy and Patient Selection. The sharks—Drs. @YJanjigianMD, Scott Paulson, @GIcancerDoc, and Ryan Corcoran—will put both cases under the microscope before deciding who gets the deal. Don't miss it! Nov 5–7, 2026 | Austin, TX | Free registration: https://t.co/JL2wHeOk9P #GIOncology #GastricCancer #HER2 #Immunotherapy #TexasGI26

[Texas GI Conference @TXGIconference]

The Tank is officially open at #TexasGI26!🦈 Mr. Wonderful himself dropped in to set the stage for our Texas GI Tank debate on 1L HER2+ Gastric/GEJ: The Role of Immunotherapy & Patient Selection. @KlempnerSam is pitching hard that immunotherapy should stay the 1L standard, while @rutikamehtaMD is coming in with the bold counter that bispecifics are the future of 1L HER2+ disease. Waiting in the Tank are four of oncology’s sharpest minds— Drs. @YJanjigianMD, Scott Paulson, @GIcancerDoc, and Ryan Corcoran—who don’t hand out deals easily. Will one strategy land the deal, will the sharks split, or will someone hear the dreaded “For that reason… I’m out”? Join us November 5–7 in Austin at ACL Live and come see which pitch wins. https://t.co/twXDeSwM3F

[Tanios Bekaii-Saab, MD @GIcancerDoc]

@OncBrothers @smitha42 @CathyEngMD One of a kind - may she rest in eternal peace —

[Dr. Alex Ehsan, MD, PhD @DrAlexEhsan]

@GIcancerDoc @DraMartinezLago @ASCO @myESMO @GrupoTTD @BioMedCentral @sonbol_bassam @WuGiOnc @MiteshBorad @Ahn_Daniel_Onc Tanios your MOUNTAINEER work helped advance precision GI oncology. I agree biweekly gem/nab may improve tolerability alongside RAS inhibitors. The key is preserving delivered dose intensity without compromising efficacy. Neuropathy and survival matter as much as tumor response.

[Sawyer Bawek, DO @sawyer_bawek]

⭐️ Excellent Taussig Grand Rounds presentation by @GIcancerDoc!

💜 Major advancements in #pancreaticcancer treatment over the last year, with more to come!

🤩 Excited to see more updates upcoming at #ESMO26

#OncTwitter #HemOnc #MedTwitter #GIOnc #MedX @letswinpc @PanCAN

[Tanios Bekaii-Saab, MD @GIcancerDoc]

@DrAlexEhsan @DraMartinezLago @ASCO @myESMO @GrupoTTD @BioMedCentral @sonbol_bassam @WuGiOnc @MiteshBorad @Ahn_Daniel_Onc 💯- more so in the #Ras era — biweekly gem-nab when combined with #ras inhibitors will allow maintaining dose intensity which is essential to improve outcomes

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 Biweekly gemcitabine + nab-paclitaxel | mPDAC

📚 Systematic review | (N=5, retrospective)
⏳ mOS 9.1–10 mo | mPFS 4.8–5.4 mo
✅ Lower G≥3 neutropenia, febrile neutropenia & neuropathy
⚠️ No randomized comparisons

💡 Biweekly GA: feasible, effective and better tolerated.

🔗 https://t.co/TEnZAXZCw9

@OncoAlert

[Erika Ruiz-Garcia, MD, FASCO @Betzabe100]

There's no better way to learn and exchange insights than alongside top GI cancer experts from the US-Special thanks to Drs. @GIcancerDoc, @EileenMOReilly,#Chistopher Lieu, @KristenCiombor, #John H. Strickler @gotoPER @incanMX

[Wungki Park, MD MS @CentralParkWMD]

@GIcancerDoc @EileenMOReilly
#ISGIO26 in Ft Lauderdale @gotoPER

Full circle ⭕️ at ISGIO.

From my first year in Bassel El-Rayes’ lab @WinshipAtEmory @EmoryMedicine and first ASCO abstract with Tanios Bekaii-Saab → nearly 15 years learning from & partnering with Eileen M O’Reilly → now brainstorming the next frontier of #RAS therapeutics with Chris Lieu, @ChristopherLieu John Strickler & many friends.

Mentors 👉collaborators 👉 friends.

The RAS era is here. Much more to build together. 🧬

#KRAS #GIOncology #PancreaticCancer
@MSK_DeptOfMed @CpcrMsk

[Dr. Nina Niu Sanford @NiuSanford]

Enjoyed this session & learned a lot!

Both TARE & SBRT can deliver ablative RT in HCC. Key q is which approach is best suited for a given pt/tumor.

Sharing some of my slides below re: decision-making b/w the 2 modalities.

TY to @GIcancerDoc & @EileenMOReilly for the invite.

[OncoAlert @OncoAlert]

🚨 Join us at the 2026 International Symposium of Gastrointestinal Oncology (#ISGIO2026), October 2–3, 2026!

🆓 FREE registration with code: ONCOALERT
👉 Register: https://t.co/AFiPe6Q9yG

This multidisciplinary program covers the latest advances in GI cancer research, biomarkers, and personalized treatment. Through expert discussions and interactive sessions, ISGIO will help clinicians navigate the evolving landscape of GI oncology and optimize patient care.

Brought to you by our collaborators at @GotoPER, featuring:
@GIcancerDoc @EileenMOReilly @BeauToskichMD @NiuSanford @SunnieSKim @mdmanishshah @drjasonstarr @Chelsie_Sievers @KristenCiombor @Betzabe100 @whallradonc @OncoThor @DianeReidyLagun @NbmerchantMD @CentralParkWMD @PedroUson @DrElkhoueiry @LizzySmyth1 @BasselElRayesMD @PaulaSmithMDPhD @WuGiOnc

[Wungki Park, MD MS @CentralParkWMD]

The best part of #AACRPanc26: the people. 💜 

Mentors and mentees.
Friends and collaborators.
Scientists, clinicians and patient advocates.

Different perspectives, one ☝️united front🛡️against #PancreaticCancer.

Science brings us together.
Friendship and shared purpose keep us moving forward.

Grateful for this community. @AACR
#PDAC #KRAS #TeamScience
💜 @MSK_DeptOfMed @MSKCancerCenter @CpcrMsk @PanCAN @lustgartenfdn @NatPancFdn @Pankind_Aus
@EileenMOReilly @Jonathanwlee23 @BenWestphalen @GIcancerDoc Collin Weekes @OncoDailyGI @oncodaily

[Tanios Bekaii-Saab, MD @GIcancerDoc]

@MayoCancerCare @MayoClinic

[AACR @AACR]

Conference cochairs @EileenMOReilly and Colin D. Weekes joined Christoph Benedikt Westphalen and Tanios Bekaii-Saab to discuss "Smarter Clinical Trials and Precision Development" in a plenary session at #AACRpan26. @BenWestphalen @GIcancerDoc

[Tanios Bekaii-Saab, MD @GIcancerDoc]

@DocMCotant The missing arm in idea — 3 month of oxaliplatin based treatment followed by 3 months of fluoropyrimidine for high risk pts — 5FU is the biggest positive differentiator — oxaliplatin is toxic sugar on top -

[Tanios Bekaii-Saab, MD @GIcancerDoc]

Less is more — demonstrated once again — neuropathy once established is a lifelong toxicity for patients to carry and this study demonstrates that we can give our patients back their lives without significant compromise -this study is very consequential as we have moved to the molecularly targeted era in advanced stages - limited induction chemo then let biology dominate the rest of the course @OncBrothers @OncoAlert @MayoCancerCare

[Bassam Sonbol @sonbol_bassam]

This is one of my favorite papers we’ve published , led by our great Mayo resident @WallaceKleinS
“Reduced oxaliplatin exposure in gastrointestinal cancers: A
systematic review and meta-analysis”

We already know from maintenance trials in mCRC that stopping oxaliplatin after 3–4 months is not detrimental for PFS/OS and is associated with less neuropathy.
The question in 2026: what is the evidence in mCRC, the adjuvant setting, and other GI cancers? Is there a situation where oxaliplatin is still needed beyond 3–4 months of induction? In other words — is reduced oxaliplatin exposure associated with worse DFS or PFS across GI cancers?
We did a meta-analysis across GI cancers and settings:
• No statistically significant survival difference overall
• Lower neuropathy and grade ≥3 adverse events
Take-home: don’t keep oxaliplatin going beyond 3–4 months. These findings support limiting exposure to improve the therapeutic index of oxaliplatin-based chemo across GI settings.

https://t.co/GXx2p5NeEZ

@OncoAlert @MayoCancerCare #GIonc @GIcancerDoc @WallaceKleinS

[Thor Halfdanarson @OncoThor]

Excellent work, practical and immediately applicable to my (and maybe your) clinic. And I got to meet @WallaceKleinS this week which made it even better...

[OncoAlert @OncoAlert]

Join us at 2026 International Symposium of Gastrointestinal Oncology on October 2–3, 26 🚨 FREE🆓 REGISTRATION with Code: ONCOALERT
REGISTER 👉 https://t.co/7Z5rqPRsvP

This multidisciplinary program focuses on the latest advances in GI cancer research, biomarkers, and personalized treatment. Through expert discussions and interactive sessions, ISGIO will provide insights to help clinicians navigate the evolving landscape of gastrointestinal oncology and optimize patient care. Brought to you from our collaborators at @GotoPER

@GIcancerDoc, @EileenMOReilly, @BeauToskichMD, @NiuSanford, @SunnieSKim, @mdmanishshah, @drjasonstarr, @Chelsie_Sievers, @KristenCiombor, @Betzabe100, @whallradonc, @OncoThor, @DianeReidyLagun, @NbmerchantMD, @CentralParkWMD, @PedroUson, @DrElkhoueiry, @LizzySmyth1, @BasselElRayesMD, @PaulaSmithMDPhD @WuGiOnc

[Texas GI Conference @TXGIconference]

Inaugural Debate Theme Reveal: Texas GI Tank 🦈 One of the biggest questions in GI oncology is heading into the Tank: 1L HER2+ Gastric/GEJ: The Role of Immunotherapy & Patient Selection. Four sharks are ready to do some serious clinical due diligence: @YJanjigianMD, Scott Paulson, @GIcancerDoc, and Ryan Corcoran. They'll challenge assumptions, scrutinize the data, and decide which strategy is worth investing in. Because in the Texas GI Tank, evidence is the currency, data drives the valuation, and only the strongest pitch earns the sharks' buy-in. Who's making the pitch? Who's taking which side? Stay tuned. Nov. 5-7 | Austin, TX | Free registration: https://t.co/cWB0jsTr6q 40+ faculty, up to 11.5 CE credits, and one debate that should have the whole room leaning forward. #TexasGI26 #GIOncology #GastricCancer #HER2 #Immunotherapy

[PER @gotoPER]

KRAS used to mean limited options. Not anymore.

Join @GIcancerDoc, @EileenMOReilly, @BasselElRayesMD, @CentralParkWMD & Dr. Strickler at ISGIO's Spotlight CE Session: Precision Pathways in RAS-Mutant GI Malignancies.

📅Oct 2–3 📍Ft. Lauderdale & Virtual https://t.co/hOi9Xn9KGM